A Study of RAY1225 in Participants With Type 2 Diabetes

Summary

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

Timeline

Start

2024-02-26

Primary completion

2025-12-20

Completion

2025-12-20

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “初步结果表明，RAY1225注射液在中国成人2型糖尿病参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。” raynovent.com ↗

Drugs

Indications